Skip to content

Low Dose hCG in the Late Follicular Phase

Among ICSI Patients Undergoing Antagonist Protocols With Recombinant FSH, Does Replacement of Recombinant FSH by 200 IU of hCG in the Late Follicular Phase Compared With Continuing Recombinant FSH, Result in a Similar Number of Oocytes?

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00750100
Enrollment
70
Registered
2008-09-10
Start date
2007-09-30
Completion date
2008-11-30
Last updated
2010-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

infertility, IVF, hCG, primary infertility, secondary infertility, patients requiring in-vitro fertilisation

Brief summary

In this study,the investigators compared two protocols for controlled ovarian hyperstimulation in infertility patients requiring IVF. In the control group, the patient undergoes a standard antagonist protocol. In the study group, the administration of gonadotropins is stopped in the late follicular phase and replaced by low dose human chorionic gonadotropins. The primary endpoint of the study is the number of oocytes retrieved in both groups.

Interventions

DRUGhuman chorionic gonadotropin

hCG 200IU in the late follicular phase

200 IU per day during controlled ovarian stimulation

Sponsors

Universitair Ziekenhuis Brussel
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 36 Years
Healthy volunteers
No

Inclusion criteria

* \< 36 years on day of randomisation * FSH \< 12 in the early follicular phase * Normal ultrasound scan * BMI between 18 and 29 (both inclusive) * Randomisation at outpatient clinic

Exclusion criteria

* Endometriosis ≥ grade 3 * PCO syndrome * Poor responder * Endocrine or metabolic abnormalities

Design outcomes

Primary

MeasureTime frame
Number of oocytes in both treatment groupsup to 9 months

Secondary

MeasureTime frame
Duration of stimulation in both treatment groups, amount of gonadotropins consumed in each treatment groupup to 9 months

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026